<DOC>
	<DOCNO>NCT00586703</DOCNO>
	<brief_summary>Evaluate safety natural killer ( NK ) cell infusion use CD56 monoclonal antibody select Miltenyi Biotec system follow nonmyeloablative stem cell transplantation ( SCT ) mismatch donor . This pilot study evaluate toxicity include mortality , occurrence acute graft versus host disease ( aGVHD ) severe toxicity .</brief_summary>
	<brief_title>Safety Trial NK Cell DLI 3-5/6 Family Member Following Nonmyeloablative ASCT</brief_title>
	<detailed_description>The use non-selected donor lymphocyte infusion ( DLIs ) ( help early immune recovery induce antitumor response ) follow nonmyeloablative allogeneic stem cell transplantation ( ASCT ) also complicate risk acute graft versus host disease ( aGVHD ) 30-40 % patient experience grade III-IV aGVHD . Data suggest use natural killer ( NK ) cell ( instead nonselected DLIs ) setting may mediate graft versus tumor ( GVT ) effect independently aGVHD . This pilot study design evaluate efficacy toxicity donor natural killer ( NK ) cell selection infusion follow nonmyeloablative allogeneic stem cell transplantation mismatch donor .</detailed_description>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<criteria>Patients undergone nonmyeloablative allogeneic transplant , use 35/6 HLA match sibling donor . Measureable disease need study entry . Performance status must Karnofsky 50100 % . Donor cellular engraftment least 2.5 % nonmyeloablative procedure . â‰¤ Grade 2 acute GVHD time infusion NK cell infusion . Patients treat acute GVHD must stable dose therapy ( increase immunosuppressive therapy 2 week plan NKI ) . The dosage/level immunosuppressive therapy time NKI great 1 mg/kg prednisone daily mycophenolate 1000 mg bid daily cyclosporine target level 200 equivalent . Estimated survival least 8 week . Age &gt; equal 18 year age . Pregnant lactate woman , Patients major medical psychiatric illness , treat physician feel , could seriously compromise tolerance protocol . Patients biopsy proven overall Grade 4 GVHD lasting longer 7 day , nonmyeloablative therapy , eligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Stem cell transplant</keyword>
	<keyword>mismatch donor</keyword>
	<keyword>NK infusion</keyword>
</DOC>